Today: 14 May 2026
Browse Category

Pharmaceuticals 30 November 2025 - 4 December 2025

Bristol Myers Squibb (BMY) Stock Today: Cobenfy Trial Twist, AI Drug Discovery Milestone and $6.7 Billion Lawsuit Shape the 2026 Outlook

Bristol Myers Squibb (BMY) Stock Today: Cobenfy Trial Twist, AI Drug Discovery Milestone and $6.7 Billion Lawsuit Shape the 2026 Outlook

Bristol Myers Squibb shares rallied this week, trading near $50.55 after news on its Alzheimer’s drug Cobenfy, an AI drug discovery milestone, and a key lawsuit ruling. The company declared a $0.62 quarterly dividend, bringing the annual yield to about 4.9%. Market cap stands at $104 billion. Despite the rebound, BMY shares remain down roughly 15% for 2025.
4 December 2025
··
Johnson & Johnson (JNJ) Stock on December 3, 2025: Analyst Upgrades, Options Signals and New Drug Wins at Near‑Record Highs

Johnson & Johnson (JNJ) Stock on December 3, 2025: Analyst Upgrades, Options Signals and New Drug Wins at Near‑Record Highs

Johnson & Johnson traded near $206 on Wednesday, close to its 52-week high after a 40% rally this year. Guggenheim reiterated a Buy rating and $206 target, citing strong multiple myeloma trial results. Barclays raised its target to $197 but kept an Equal Weight rating. The company launched a vision-care campaign with Naomi Watts and received European approval for its autoimmune drug IMAAVY.
4 December 2025
··
Amgen (AMGN) Stock Hits New 52‑Week High as Obesity Drug Bets and Analyst Upgrades Fuel 2025 Rally

Amgen (AMGN) Stock Hits New 52‑Week High as Obesity Drug Bets and Analyst Upgrades Fuel 2025 Rally

Amgen shares closed at $345.42 on December 3, 2025, up 2% and setting a new 52-week high near $345.95. The stock has gained about 35% year-to-date and over 25% in the past year. Amgen beat Q3 earnings forecasts and raised full-year guidance, but analysts’ 12-month targets mostly remain below current prices. The consensus rating ranges from “Hold” to “Moderate Buy.”
3 December 2025
··
Pfizer Stock (PFE) Today – Price, Metsera Obesity Bet, RSV Vaccine Tailwinds and 2026 Forecast (3 December 2025)

Pfizer Stock (PFE) Today – Price, Metsera Obesity Bet, RSV Vaccine Tailwinds and 2026 Forecast (3 December 2025)

Pfizer shares traded at $25.60 late December 3, 2025, near the midpoint of their 52-week range and well below 2021 highs. The stock yields about 6.5–7% and trades at 8–9x forward earnings after a $10 billion obesity-drug deal. Technical analysis points to support near $24.95 and resistance around $26.10. Market capitalization stands near $144 billion.
3 December 2025
···
Regeneron Pharmaceuticals (REGN) Stock Outlook: Morgan Stanley Downgrade, Eylea HD Win and Gene‑Editing Push – December 3, 2025Regeneron

Regeneron Pharmaceuticals (REGN) Stock Outlook: Morgan Stanley Downgrade, Eylea HD Win and Gene‑Editing Push – December 3, 2025Regeneron

Regeneron shares traded near $725 midday December 3, down 2%, after Morgan Stanley downgraded the stock to Equal Weight with a $767 target, citing limited near-term upside. Eylea HD received U.S. approval for less frequent dosing in retinal vein occlusion. Market cap stands at about $77 billion, with a 0.5% dividend yield and trailing P/E of 17–18. Year-to-date total return is roughly 3%.
3 December 2025
··
Bristol-Myers Squibb (BMY) Stock Today: Celgene Lawsuit Shock, ASH 2025 Momentum and 2026 Forecasts

Bristol-Myers Squibb (BMY) Stock Today: Celgene Lawsuit Shock, ASH 2025 Momentum and 2026 Forecasts

A U.S. judge on Dec. 1, 2025, revived a $6.7 billion lawsuit against Bristol-Myers Squibb over Celgene contingent value rights, sending BMY shares down 1.89% to $48.25. The stock marked its third straight loss, underperforming peers as legal risks weighed despite positive hematology data at ASH 2025. Market cap stood at about $98 billion. Trading volume was below average at 14.5 million shares.
3 December 2025
··
Merck (MRK) Stock on December 2, 2025: Dividend Hike, FDA Wins and Fresh Wall Street Targets

Merck (MRK) Stock on December 2, 2025: Dividend Hike, FDA Wins and Fresh Wall Street Targets

Merck shares traded near $101 on December 2, 2025, down about 1%, with a market cap above $250 billion after a 22% rally in November. The company raised its quarterly dividend to $0.85 per share, effective January 2026. Merck’s stock remains below its 52-week high of $105.84 and trades at a forward P/E of 11–11.5x, below sector averages.
2 December 2025
···
Johnson & Johnson (JNJ) Stock Near Record Highs: New EU Drug Approval, Oncology Deal and 2026 Outlook

Johnson & Johnson (JNJ) Stock Near Record Highs: New EU Drug Approval, Oncology Deal and 2026 Outlook

Johnson & Johnson closed at $206.92 on December 2, just below its record high of $207.56 from November 26. The company’s market cap stands near $500 billion after a 30% year-to-date stock surge, outpacing the S&P 500. Recent gains follow strong earnings, higher 2025 guidance, a new EU drug approval, and a $3.05 billion oncology acquisition.
2 December 2025
··
Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

Eli Lilly shares traded near $1,060 midday December 2, just below record highs, after a year of sharp gains fueled by obesity and diabetes drugs. The company cut U.S. self-pay prices for Zepbound on December 1, following a federal deal to lower GLP-1 prices. Lilly’s market cap briefly topped $1 trillion in November, the first for a healthcare firm. WHO issued its first guideline recommending GLP-1 drugs for obesity on December 1.
2 December 2025
··
GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK closed near 1,783p in London on 2 December 2025, just below its 52-week high, after strong Q2 and Q3 results lifted shares nearly 40% over 12 months. Q3 sales rose 8% at constant exchange to £8.5 billion, with oncology up 39% and core EPS up 14%. The ADR ended at $47.19 in New York. Analyst focus remains on the company’s growth pipeline and 2031 revenue targets.
2 December 2025
····
Bayer Stock Rockets on U.S. Roundup Breakthrough – Is the 13% Rally the Start of a Trend?

Bayer Stock Rockets on U.S. Roundup Breakthrough – Is the 13% Rally the Start of a Trend?

Bayer shares jumped about 13% to a year high near €34–35 on Xetra after the U.S. Solicitor General backed Bayer’s request for Supreme Court review in the Roundup glyphosate case. The move follows renewed analyst upgrades and fresh pipeline news. Bayer says 132,000 of 197,000 Roundup claims have been resolved or declared ineligible as of October 2025.
2 December 2025
··
AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

AbbVie shares closed near $225 on December 1, 2025, valuing the company at about $400 billion. Q3 net revenue rose 9.1% to $15.78 billion, with adjusted EPS of $1.86 topping estimates. The company raised its 2025 profit forecast and approved a 5.5% dividend increase. Immunology sales climbed, while Humira revenue dropped below $1 billion.
1 December 2025
····
GSK Stock on 1 December 2025: Big 2025 Rally, Blenrep’s Comeback and a New CEO – What Investors Need to Know Now

GSK Stock on 1 December 2025: Big 2025 Rally, Blenrep’s Comeback and a New CEO – What Investors Need to Know Now

GSK shares closed at $47.9 on November 28, just below a 52-week high, after a year-to-date gain of about 30–40%. The company beat earnings expectations in Q2 and Q3, raised full-year guidance, and saw its cancer drug Blenrep re-approved in major markets. CEO Emma Walmsley will step down December 31, with Luke Miels to take over January 1. Most analysts rate the stock a “Hold” despite recent outperformance.
1 December 2025
··
AbbVie (ABBV) Stock Outlook Before the December 1, 2025 Open: Skyrizi’s Canada Win, Medicare Cuts and Fresh Analyst Targets

AbbVie (ABBV) Stock Outlook Before the December 1, 2025 Open: Skyrizi’s Canada Win, Medicare Cuts and Fresh Analyst Targets

AbbVie closed November 30 at about $227, down 3% for the week but up over 30% in the past year. Shares slipped after news of steep Medicare price cuts for Linzess and Vraylar, while Canada approved public reimbursement for Skyrizi. AbbVie raised its 2026 dividend by 5.5%, with a forward yield just above 3%. Wall Street’s 12-month price target averages $240–$247.
30 November 2025
·
Eli Lilly (LLY) Stock Outlook Before Market Open on December 1, 2025: Trillion‑Dollar Rally Pauses After Policy Shock

Eli Lilly (LLY) Stock Outlook Before Market Open on December 1, 2025: Trillion‑Dollar Rally Pauses After Policy Shock

Eli Lilly shares closed at $1,075.47 on Friday, down 2.6% after a month-long rally that briefly pushed its market value above $1 trillion. The stock remains up about 39% year-to-date and surged roughly 26–31% in November, driven by demand for its obesity drugs. Investors are weighing recent policy headlines and valuation concerns ahead of Monday’s open. No pre-market quote was available with US markets closed over the weekend.
30 November 2025
··
Merck (MRK) Stock on November 30, 2025: Price, Fresh Analyst Calls, Cidara Deal and Dividend Outlook

Merck (MRK) Stock on November 30, 2025: Price, Fresh Analyst Calls, Cidara Deal and Dividend Outlook

Merck shares closed at $104.83 on November 28, 2025, near their 52-week high after a 22% surge in the past month. The stock spent much of early autumn in the mid-$80s before jumping above $100 following third-quarter earnings and positive November news. Analysts are split on valuation, with some models showing MRK as fairly priced and others suggesting significant upside.
30 November 2025
··
1 … 30 31 32 33 34 … 40

Stock Market Today

  • 1 Stock Under $50 With Strong Growth Potential, 2 Facing Market Headwinds
    May 13, 2026, 9:53 PM EDT. Stocks priced between $10 and $50 offer unique long-term investment opportunities but come with risks. Alarm.com (NASDAQ:ALRM) trades at $47.67 with modest 8.4% billings growth and stagnant operating margins, signaling potential underperformance. Marcus & Millichap (NYSE:MMI), at $30.42, shows weak 1.9% annual revenue growth and poor free cash flow margins, raising concerns about its growth prospects. In contrast, IMAX (NYSE:IMAX) stands out with a $35.31 share price, boasting impressive 23.5% annual revenue growth and expanded free cash flow margins, indicating robust fundamentals and potential for long-term gains.

Latest articles

Enovix Stock Drops After Q1 Beat as Smartphone Battery Tests Stay Unfinished

Enovix Stock Drops After Q1 Beat as Smartphone Battery Tests Stay Unfinished

14 May 2026
Enovix shares dropped 12.9% to $6.35 after hours Wednesday despite beating first-quarter revenue and adjusted-loss estimates. The decline followed news that smartphone battery qualification remains unfinished, with the company passing 72 of 75 customer tests. Revenue rose 49% to $7.6 million. Enovix cited progress in defense, industrial, and smart-eyewear sales.
Lightwave Logic Stock Jumps as AI-Photonics Bet Heads for a 2027 Production Test

Lightwave Logic Stock Jumps as AI-Photonics Bet Heads for a 2027 Production Test

14 May 2026
Lightwave Logic reported Q1 revenue up 27% to $29,000 and a net loss widening to $6.3 million. Shares rose 14% after the company said it is negotiating a supply and licensing deal for high-volume production in 2027. Four Fortune 500 customers are now in Stage 3 prototyping. Cash and equivalents totaled about $100 million as of May 11.
USA Rare Earth Stock Watch: Q1 Revenue, $1.75 Billion Cash and the China Supply Crunch

USA Rare Earth Stock Watch: Q1 Revenue, $1.75 Billion Cash and the China Supply Crunch

14 May 2026
USA Rare Earth reported Q1 revenue of $5.7 million and a net loss of $67 million, ending March with $1.75 billion in cash after a $1.5 billion PIPE. The company expects to sign documents this month for $1.6 billion in U.S. Commerce Department funding. Texas awarded a $14.18 million grant for the Round Top project. USA Rare Earth agreed in April to acquire Brazil’s Serra Verde for $2.8 billion.
Go toTop